PriceTargets.com logo

BioLineRx - BLRX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $360.00
  • Forecasted Upside: 11,350.38%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$3.14 As of 03/13/2025 12:43 PM ET
▼ -0.066 (-2.06%)

This chart shows the closing price for BLRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BioLineRx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BLRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BLRX

Analyst Price Target is $360.00
▲ +11,350.38% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for BioLineRx in the last 3 months. The average price target is $360.00, with a high forecast of $360.00 and a low forecast of $360.00. The average price target represents a 11,350.38% upside from the last price of $3.14.

This chart shows the closing price for BLRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in BioLineRx. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/19/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/18/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/16/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/14/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/13/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/11/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/13/2025

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/25/2024HC WainwrightLower TargetBuy ➝ Buy$840.00 ➝ $360.00
11/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$840.00 ➝ $840.00
5/29/2024HC WainwrightReiterated RatingBuy ➝ Buy$840.00 ➝ $840.00
4/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$840.00
3/26/2024HC WainwrightReiterated RatingBuy ➝ Buy$840.00
2/29/2024HC WainwrightReiterated RatingBuy ➝ Buy$840.00
11/20/2023HC WainwrightReiterated RatingBuy ➝ Buy$840.00
9/15/2023HC WainwrightBoost TargetBuy ➝ Buy$760.00 ➝ $840.00
8/31/2023HC WainwrightReiterated RatingBuy ➝ Buy$760.00
3/22/2023HC WainwrightReiterated RatingBuy
8/22/2022OppenheimerLower Target$240.00
5/4/2021Maxim GroupBoost TargetBuy$200.00 ➝ $400.00
3/1/2021HC WainwrightLower TargetBuy$880.00 ➝ $760.00
2/23/2021HC WainwrightReiterated RatingBuy$880.00 ➝ $760.00
12/16/2020HC WainwrightBoost TargetBuy$720.00 ➝ $880.00
8/7/2020Maxim GroupReiterated RatingBuy
7/20/2020HC WainwrightReiterated RatingBuy
3/13/2020OppenheimerLower Target$1,040.00 ➝ $440.00
(Data available from 3/13/2020 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/15/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/14/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/14/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/13/2024
  • 0 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/13/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/12/2025
  • 0 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/11/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/13/2025

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
BioLineRx logo
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Read More

Today's Range

Now: $3.14
Low: $3.10
High: $3.18

50 Day Range

MA: $4.26
Low: $3.07
High: $10.95

52 Week Range

Now: $3.14
Low: $2.88
High: $56.00

Volume

4,931 shs

Average Volume

64,500 shs

Market Capitalization

$10.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.39

Frequently Asked Questions

What sell-side analysts currently cover shares of BioLineRx?

The following Wall Street research analysts have issued reports on BioLineRx in the last year: HC Wainwright, and StockNews.com.
View the latest analyst ratings for BLRX.

What is the current price target for BioLineRx?

0 Wall Street analysts have set twelve-month price targets for BioLineRx in the last year. Their average twelve-month price target is $360.00, suggesting a possible upside of 11,350.4%. HC Wainwright has the highest price target set, predicting BLRX will reach $360.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $360.00 for BioLineRx in the next year.
View the latest price targets for BLRX.

What is the current consensus analyst rating for BioLineRx?

BioLineRx currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BLRX will outperform the market and that investors should add to their positions of BioLineRx.
View the latest ratings for BLRX.

What other companies compete with BioLineRx?

Other companies that are similar to BioLineRx include KALA BIO, Dyadic International, Spero Therapeutics, 23andMe and FibroBiologics. Learn More about companies similar to BioLineRx.

How do I contact BioLineRx's investor relations team?

BioLineRx's physical mailing address is 2 HAMA-AYAN STREET, MODI-IN L3, 7177871. The biotechnology company's listed phone number is (728) 642-9100 and its investor relations email address is [email protected]. The official website for BioLineRx is www.biolinerx.com. Learn More about contacing BioLineRx investor relations.